Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Several safety-relevant claims are supported (notably grapefruit increasing atorvastatin concentrations and risks of myopathy/rhabdomyolysis and liver enzyme abnormalities). However, multiple mechanism and clinical-effect claims (e.g., transporter inhibition, specific symptom constellations like dark/cola urine, general adverse effects such as headache/nausea/diarrhea, and prescriptive behavioral recommendations such as avoiding grapefruit entirely and immediate stopping) are not supported by the provided label excerpts, resulting in only partial alignment.
Category Scores
Accurate Statements
Grapefruit can increase atorvastatin exposure in the body.
7.2 Grapefruit Juice: grapefruit components inhibit CYP3A4 and can increase plasma concentrations of atorvastatin.
Compounds in grapefruit inhibit enzymes that normally help clear atorvastatin.
7.2 Grapefruit Juice: contains components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin.
Higher atorvastatin levels increase the risk of muscle-related toxicity.
7.2 Grapefruit Juice (increased plasma concentrations); 5.1 Skeletal Muscle (myopathy/rhabdomyolysis risk context with increased exposure via interacting drugs).
Muscle-related toxicity can include severe rhabdomyolysis with atorvastatin.
5.1 Skeletal Muscle: rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria reported with LIPITOR.
Statins can cause liver enzyme elevations.
5.2 Liver Dysfunction: statins associated with biochemical abnormalities of liver function; persistent transaminase elevations reported.
Muscle injury symptoms with atorvastatin may include new or worsening muscle pain, tenderness, or weakness.
5.1 Skeletal Muscle: diffuse myalgias, muscle tenderness or weakness; report unexplained muscle pain, tenderness, or weakness. 17.1 Muscle Pain also instructs to report muscle pain, tenderness, or weakness.
A clinician may check creatine kinase (CK) and liver enzymes if symptoms occur.
5.1 Skeletal Muscle (periodic CPK determinations may be considered in certain situations; and monitoring described); 17.2 Liver Enzymes (recommended LFT schedule).
A clinician may check creatine kinase (CK) and liver enzymes when symptoms suggesting muscle injury or liver problems occur.
5.1 Skeletal Muscle; 5.2 Liver Dysfunction; 17.2 Liver Enzymes (monitoring recommendations for LFTs and muscle effects).
Unsupported Statements
Compounds in grapefruit inhibit transporters that normally help clear atorvastatin.
No provided label excerpt states grapefruit inhibits transporters involved in atorvastatin clearance; 7.2 only mentions CYP 3A4 inhibition.
Clinical guidance in drug labels and prescribing information generally recommends avoiding grapefruit or limiting it strictly with atorvastatin.
Provided excerpts do not include any prescribing recommendation to avoid or limit grapefruit with atorvastatin.
Muscle injury toxicity with atorvastatin may present with dark/cola-colored urine.
Dark/cola-colored urine is not mentioned in the provided label sections (5.1, 7.2, 17.1).
Liver-related effects of statins may be associated with unusual fatigue, loss of appetite, upper abdominal pain, dark urine, or yellowing of the skin/eyes.
The provided excerpts describe biochemical abnormalities and monitoring, but do not list these specific symptom clusters.
Headache, nausea, or diarrhea are possible general statin side effects.
No provided label excerpts mention these adverse effects.
The interaction risk between grapefruit and atorvastatin is not limited to large amounts of grapefruit.
7.2 specifies 'especially with excessive grapefruit juice consumption (>1.2 liters per day)' but does not support the broader claim that interaction risk is not limited to large amounts.
Even normal grapefruit juice use can increase atorvastatin drug exposure.
Not supported by the provided label excerpts; 7.2 only characterizes increased concentrations 'especially' with excessive consumption.
Clinicians recommend avoiding grapefruit entirely with atorvastatin unless the prescriber confirms a specific small amount is acceptable.
No provided excerpt contains such avoidance/conditional allowance language.
If a person drinks grapefruit regularly with atorvastatin, stopping grapefruit and talking with a prescriber or pharmacist promptly is the safest move.
No provided excerpt provides this type of patient action recommendation.
If a person on atorvastatin has muscle symptoms including weakness, significant pain, or dark urine, they should seek medical care urgently.
Label text provided supports reporting unexplained muscle pain/tenderness/weakness promptly (5.1 and 17.1), but 'dark urine' and 'seek medical care urgently' are not supported in the cited excerpts.
The grapefruit interaction risk depends on how each statin is metabolized and transported.
Provided excerpts do not discuss statin-by-statin differences in metabolism/transport affecting grapefruit interaction risk.
Atorvastatin is one of the statins where grapefruit interaction is a well-known concern.
Not present in provided label excerpts.
Many labels advise avoiding grapefruit for atorvastatin.
Not present in provided label excerpts.
Contradictions
Important Omissions
No label-supported quantitative dosing/administration changes specific to grapefruit avoidance/limit were provided or evaluated.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported claims could lead to overconfident interpretation of grapefruit interaction magnitude/mechanism and to patient symptom interpretation (e.g., dark/cola urine) and actions not grounded in the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several safety-relevant details and mechanism/symptom descriptions are not supported by the provided label excerpts (notably transporter inhibition and specific symptom clusters and patient-action guidance).
Suggested Improvement
Restrict statements to what is explicitly supported in the provided label sections: grapefruit components inhibiting CYP3A4 and increasing atorvastatin plasma concentrations, risks of myopathy/rhabdomyolysis, and reporting unexplained muscle pain/tenderness/weakness and liver enzyme monitoring recommendations.